Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced its participation in the following upcoming investor conferences:
- 2024 Wells Fargo Healthcare Conference in Everett, MA on Thursday, September 5, 2024. Stephen Uden, M.D., Chief Executive Officer, will participate in a fireside chat at 3:45 p.m. ET.
- H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on Tuesday, September 10, 2024. Dr. Uden will present a corporate overview at 11:00 a.m. ET.
Live webcasts of the Wells Fargo fireside chat and H.C. Wainwright presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240826376744/en/
